Mangoceuticals (MGRX) Common Equity (2022 - 2026)

Mangoceuticals has disclosed Common Equity across 5 years of filings, most recently posting $12.5 million for Q2 2026.

• In Q2 2026, Common Equity fell 34.9% year-over-year to $12.5 million; the TTM figure through Jun 2026 stood at $12.5 million (down 34.9% YoY), while the FY2025 annual figure was $15.2 million, up 9.0% from the prior year.
• Common Equity came in at $12.5 million for Q2 2026 at Mangoceuticals, down from $13.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $20.3 million in Q1 2025 to a low of -$958468.0 in Q1 2024.
• Average Common Equity over 5 years is $9.8 million, with a median of $13.5 million recorded in 2026.
• Year-over-year, Common Equity tumbled 125.1% in 2024 and surged 2212.82% in 2025.
• Over 5 years, Common Equity stood at $614029.0 in 2022, then rose by 26.18% to $774754.0 in 2023, then soared by 1699.93% to $13.9 million in 2024, then increased by 9.0% to $15.2 million in 2025, then decreased by 17.6% to $12.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $12.5 million in Q2 2026, $13.5 million in Q1 2026, and $15.2 million in Q4 2025.